Trial Profile

ALX 0141 for prevention of postmenopausal osteoporosis.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALX 0141 (Primary)
Indications Postmenopausal osteoporosis
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
Sponsors Ablynx

Most Recent Events

16 Nov 2011 Status changed from active, no longer recruiting to completed, according to an Ablynx media release.
28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
25 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism (EULAR-2011) (abstract OP-0198)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com